

CHRIS HEATON-HARRIS MP



HOUSE OF COMMONS

LONDON SW1A 0AA

March 2017

Dear Constituent,

Thank you for contacting me about the availability of nusinersen in the treatment of spinal muscular atrophy (SMA).

I do appreciate SMA can be a very debilitating condition and it is important to ensure that the correct treatment and support is available to help manage the symptoms and provide people with SMA with the best possible quality of life.

I am aware that Biogen Ltd submitted a marketing authorisation application for nusinersen to the European Medicines Agency (EMA) in October 2016.

The application has been approved for accelerated assessment by the Committee for Medicinal Products for Human Use who examine evidence of the safety, efficacy and quality of new medicines proposed for licence in the EU and is under assessment. Approval for accelerated assessment allows for faster assessment by the EMA's scientific committees (within up to 150 days rather than up to 210 days).

If approved, the product will be authorised for marketing in all EU member states.

Once again, thank you again for taking the time to contact me.

Yours faithfully,

A handwritten signature in blue ink, appearing to read 'Chris'.

**CHRIS HEATON-HARRIS MP
MEMBER OF PARLIAMENT FOR DAVENTRY**